Innova Therapeutics

Innova Therapeutics is dedicated to developing innovative cancer therapies for patients which have inadequate treatment options. Innova Therapeutics was founded on the research conducted by Co-founders Nancy Klauber-DeMore, MD, FACS, Professor of Surgery and BMW Endowed Chair Cancer Research, Medical University of South Carolina (MUSC) and Cam Patterson, MD, MBA who is currently the Chancellor, University of Arkansas for Medical Sciences. Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a protein that is highly expressed in various solid cancers and shown to correlate with patient outcome. Ryan was previously CEO and co-founder of Scioderm, which is a company that developed a topical therapy for the orphan disease, Epidermolysis Bullosa. Michael Zimmer is a highly experienced executive who brings 30 years of experience as a business leader in various roles including Finance, Accounting, Operations, Supply Chain, Business and Employee Development. Lenon’s therapeutic expertise in clinical trials is broad in areas including Oncology, Dermatology, Analgesia, Cardiovascular, Genitourinary, hematology, Metabolic Disorders, Neurology, Ophthalmology, Pulmonary/Allergy, and Rheumatology. Tap is the Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York. The focus on pediatric osteosarcoma as one of the initial targets will allow a fast-regulatory approval, with the opportunity to obtain a Rare Pediatric Disease priority review voucher.